BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27649261)

  • 21. Correlation between methylation level of the
    Huang X; Hao Q; Fang Q; Zhang P; Wei H; Wang Y; Wang J; Mi Y
    Pharmacogenomics; 2023 Apr; 24(5):261-268. PubMed ID: 36999405
    [No Abstract]   [Full Text] [Related]  

  • 22. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
    Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis.
    Vagace JM; Caceres-Marzal C; Jimenez M; Casado MS; de Murillo SG; Gervasini G
    Am J Hematol; 2011 Jan; 86(1):98-101. PubMed ID: 21064136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
    Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
    Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
    Giletti A; Vital M; Lorenzo M; Cardozo P; Borelli G; Gabus R; Martínez L; Díaz L; Assar R; Rodriguez MN; Esperón P
    Eur J Pharm Sci; 2017 Nov; 109():480-485. PubMed ID: 28887233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?
    Kodidela S; Suresh Chandra P; Dubashi B
    Eur J Clin Pharmacol; 2014 Mar; 70(3):253-60. PubMed ID: 24370659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
    Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
    Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia.
    Kodidela S; Pradhan SC; Dubashi B; Basu D
    Eur J Clin Pharmacol; 2015 Nov; 71(11):1349-58. PubMed ID: 26335211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia.
    López-López E; Gutiérrez-Camino Á; Piñán MÁ; Sánchez-Toledo J; Uriz JJ; Ballesteros J; García-Miguel P; Navajas A; García-Orad Á
    PLoS One; 2014; 9(3):e91261. PubMed ID: 24614921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment.
    Gutierrez-Camino Á; Umerez M; Lopez-Lopez E; Santos-Zorrozua B; Martin-Guerrero I; de Andoin NG; Ana S; Navajas A; Astigarraga I; Garcia-Orad A
    Pharmacogenomics; 2018 Dec; 19(18):1403-1412. PubMed ID: 30479191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
    Yousef AM; Farhad R; Alshamaseen D; Alsheikh A; Zawiah M; Kadi T
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):755-762. PubMed ID: 30684021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia.
    Li M; Kong XY; Wang SM
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):77-87. PubMed ID: 36463535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia.
    Kałużna E; Strauss E; Zając-Spychała O; Gowin E; Świątek-Kościelna B; Nowak J; Fichna M; Mańkowski P; Januszkiewicz-Lewandowska D
    Eur J Pharmacol; 2015 Dec; 769():93-9. PubMed ID: 26528799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
    Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
    Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia.
    Zobeck M; Bernhardt MB; Kamdar KY; Rabin KR; Lupo PJ; Scheurer ME
    Pharmacotherapy; 2023 Mar; 43(3):205-214. PubMed ID: 36764694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
    Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
    Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
    Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
    Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of microRNA polymorphisms on high-dose methotrexate-related hematological toxicities in pediatric acute lymphoblastic leukemia.
    Zhan M; Liu T; Zhang Z; Wang G; Cao Z; Li X; Zeng H; Mai H; Chen Z
    Front Pediatr; 2023; 11():1153767. PubMed ID: 37384310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.